TECH
Overvalued by 24.3% based on the discounted cash flow analysis.
Market cap | $7.98 Billion |
---|---|
Enterprise Value | $8.19 Billion |
Dividend Yield | $0.32 (0.6337888690829869%) |
Earnings per Share | $1.07 |
Beta | 1.45 |
Outstanding Shares | 158,431,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 50.58 |
---|---|
PEG | 187.11 |
Price to Sales | 7.11 |
Price to Book Ratio | 3.83 |
Enterprise Value to Revenue | 6.85 |
Enterprise Value to EBIT | 39.91 |
Enterprise Value to Net Income | 51 |
Total Debt to Enterprise | 0.05 |
Debt to Equity | 0.18 |
No data
No data
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems , No...